OPKO Health, Inc. Long-term Line of Credit, Noncurrent
OPKO Health, Inc. (OPK) had Long-term Line of Credit, Noncurrent of $0 as of 2020-12-31, per its 10-K filed 2021-02-18.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermLineOfCredit · last filed 2021-02-18
- 2020-12-31: Long-term Line of Credit, Noncurrent $0.00.
- 2020-09-30: Long-term Line of Credit, Noncurrent $0.00.
- 2020-06-30: Long-term Line of Credit, Noncurrent $51.49M.
- 2020-03-31: Long-term Line of Credit, Noncurrent $39.31M.
| Period end | Long-term Line of Credit, Noncurrent |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-18 |
| 2020-09-30 | $0.00 10-Q · filed 2020-10-29 |
| 2020-06-30 | $51.49M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $39.31M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $44.75M 10-K · filed 2021-02-18 |
| 2019-09-30 | $50.64M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $65.11M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 |
| 2018-12-31 | $105.20M 10-K · filed 2020-03-02 |
| 2018-09-30 | $104.03M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $105.54M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $105.09M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $104.15M 10-K · filed 2019-03-01 |
| 2017-09-30 | $93.31M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $69.70M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $39.24M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $38.81M 8-K · filed 2019-01-29 |
| 2015-12-31 | $72.11M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |